Pfizer Media Center - News Releases via MedWorm.com MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Pfizer Media Center - News Releases' source. Sat, 10 Oct 2009 19:36:00 +0100 Pfizer Invites Public to View and Listen to Webcasts of Pfizer Presentations at Healthcare Conferences http://www.medworm.com/index.php?rid=466415&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D156 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=466415 Mon, 12 Mar 2007 19:00:00 +0100 466415 Lipitor Receives FDA Approval for Five New Indications in Patients With Heart Disease http://www.medworm.com/index.php?rid=454808&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D155 The Only-Approved Cholesterol-Lowering Medication for Reducing the Risk of Hospitalization for Heart Failure (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=454808 Wed, 07 Mar 2007 15:18:00 +0100 454808 Lipitor Significantly Reduced the Risk of Serious Cardiovascular Events Compared With Simvastatin in an 80,000-Patient Analysis of a Real-World Managed Care Database http://www.medworm.com/index.php?rid=442605&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D154 Real-World Implications for Patients, Providers and Healthcare Systems Seeking Quality Care; Pfizer to Further Explore These Benefits in Partnership with Others (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=442605 Fri, 02 Mar 2007 17:40:00 +0100 442605 Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients http://www.medworm.com/index.php?rid=442607&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D153 Pivotal Data Presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI) (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=442607 Thu, 01 Mar 2007 20:00:00 +0100 442607 Pfizer Wins Challenge to Norvasc Patent by Mylan http://www.medworm.com/index.php?rid=442609&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D152 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=442609 Tue, 27 Feb 2007 20:28:00 +0100 442609 Pfizer Board of Directors Elects Constance J. Horner to Serve as Lead Director http://www.medworm.com/index.php?rid=432459&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D151 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=432459 Fri, 23 Feb 2007 15:30:00 +0100 432459 Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product http://www.medworm.com/index.php?rid=432460&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D150 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=432460 Fri, 23 Feb 2007 13:07:00 +0100 432460 Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe http://www.medworm.com/index.php?rid=412168&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D149 If Approved, Maraviroc will be the First in a New Class of Medications Available for HIV Treatment (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=412168 Tue, 13 Feb 2007 12:00:00 +0100 412168 Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label http://www.medworm.com/index.php?rid=405717&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D147 New Labeling Based on Efficacy Data from a Large Phase 3 Clinical Trial Which Showed Superiority of Sutent to Standard Therapy Across Key Endpoints (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=405717 Thu, 08 Feb 2007 20:50:00 +0100 405717 New Analysis Shows That Intensive Lipitor Therapy Cuts the Risk of Hospitalizations Due to Heart Failure in Patients with Coronary Heart Disease http://www.medworm.com/index.php?rid=404488&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D146 - - - (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404488 Wed, 07 Feb 2007 19:52:00 +0100 404488 Pfizer to Acquire BioRexis to Access Novel Technology Platform and Early Stage Diabetes Pipeline http://www.medworm.com/index.php?rid=404489&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D145 Acquisition is a Further Step in Pfizer Strategy to Accelerate Business Development and Licensing Activity (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404489 Thu, 01 Feb 2007 15:00:00 +0100 404489 Court Rules In Pfizer's Favor In Norvasc Patent Case, Finds Synthon Obtained Patent By Inequitable Conduct http://www.medworm.com/index.php?rid=404490&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D144 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404490 Wed, 31 Jan 2007 21:02:00 +0100 404490 Pfizer Gains Favorable Ruling From Canadian Court on Lipitor Basic Patent, Will Appeal Ruling on Calcium Salt Patent http://www.medworm.com/index.php?rid=404491&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D143 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404491 Fri, 26 Jan 2007 01:44:00 +0100 404491 Pfizer Announces Priorities to Drive Improved Performance, Position Company for Future Success and Enhance Total Shareholder Return http://www.medworm.com/index.php?rid=404492&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D142 Company's Plan Focuses On: (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404492 Mon, 22 Jan 2007 17:28:00 +0100 404492 Pfizer Achieves Key 2006 Financial Targets http://www.medworm.com/index.php?rid=404493&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D141 - Full-Year 2006 Revenues Grew 2 Percent to $48.4 Billion, Key Products Substantially Attained Targets, Nine Exceeded $1 Billion in Sales (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404493 Mon, 22 Jan 2007 11:30:00 +0100 404493 Pfizer Animal Health Completes Acquisition of Embrex, Inc. http://www.medworm.com/index.php?rid=404494&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D140 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404494 Fri, 19 Jan 2007 22:02:00 +0100 404494 Pfizer’s Sutent® is Granted Full Marketing Authorization for First-Line Use in Advanced Kidney Cancer in the European Union http://www.medworm.com/index.php?rid=404495&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D139 Full marketing authorization and extension of indication to first-line treatment of advanced and/or metastatic renal cell carcinoma (MRCC). (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404495 Thu, 18 Jan 2007 09:00:00 +0100 404495 Pfizer Invites Public to View and Listen to Webcast of January 22 Meeting with Analysts http://www.medworm.com/index.php?rid=404496&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D138 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404496 Tue, 16 Jan 2007 19:06:00 +0100 404496 Pfizer Completes Sale of Consumer Healthcare Business http://www.medworm.com/index.php?rid=404497&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D137 Company to Use Proceeds from Sale Combined with Strong Operating Cash Flow to Invest in Growth of Core Pharmaceutical Business (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404497 Wed, 20 Dec 2006 22:36:00 +0100 404497 Pfizer Launches On-Line Site for Tracking Development Compounds Across its Largest-Ever Pipeline http://www.medworm.com/index.php?rid=404498&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D136 New Site Part of Pfizer Commitment to Enhanced Transparency for Investors As Well As Scientific and Medical Communities (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404498 Wed, 20 Dec 2006 15:00:00 +0100 404498 Australian Federal Court Upholds Basic Lipitor Patent, Preventing Launch of Generic Ranbaxy Product http://www.medworm.com/index.php?rid=404499&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D135 Lipitor Protected from Generic Competition in Australia until 2012 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404499 Wed, 20 Dec 2006 00:08:00 +0100 404499 Pfizer Board of Directors Names Chief Executive Officer Jeffrey B. Kindler Chairman of the Board http://www.medworm.com/index.php?rid=404500&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D134 Pfizer Increases Dividend 21 Percent to 29 Cents Per Share for the First Quarter of 2007 as Part of Continuing Focus on Total Return to Shareholders (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404500 Mon, 18 Dec 2006 21:30:00 +0100 404500 New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium http://www.medworm.com/index.php?rid=404501&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D133 Pfizer Begins a Phase III Trial to Study Sutent® in Patients with Advanced Breast Cancer (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404501 Thu, 14 Dec 2006 18:09:00 +0100 404501 Court Denies Novo Nordisk's Motion for Preliminary Injunction Against Exubera http://www.medworm.com/index.php?rid=404502&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D132 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404502 Thu, 14 Dec 2006 16:31:00 +0100 404502 Canadian Federal Court Upholds Lipitor Patent, Decision Will Prevent Launch of Generic Product Until 2010 http://www.medworm.com/index.php?rid=404503&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D131 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404503 Fri, 08 Dec 2006 13:45:00 +0100 404503 In Interests of Patient Safety, Pfizer Stops All Torcetrapib Clinical Trials; Company Has Notified FDA and is in the Process of Notifying All Clinical Investigators and Other Regulatory Authorities http://www.medworm.com/index.php?rid=404504&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D130 Decision Based on Recommendation Received Today of Independent Data Safety Monitoring Board for ILLUMINATE Trial; Pfizer Will Discontinue Development of Compound (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404504 Sun, 03 Dec 2006 02:11:00 +0100 404504 Pfizer Announces Plans to Establish Expanded Access Program for Maraviroc, Investigational HIV CCR5 Antagonist http://www.medworm.com/index.php?rid=404505&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D129 Broad Access Program for Patients with Limited Available Treatment Options (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404505 Fri, 01 Dec 2006 05:01:00 +0100 404505 Pfizer Presents Robust and Diversified Product Pipeline Across 11 Therapeutic Areas http://www.medworm.com/index.php?rid=404506&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D128 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404506 Thu, 30 Nov 2006 13:12:00 +0100 404506 As Initial Step in Transformation Strategy and Review of All Business Units, Pfizer to Align U.S. Sales Organization to Support Its Key Products and Customer Needs http://www.medworm.com/index.php?rid=404507&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D126 Pfizer Says Representatives Are Critical Competitive Advantage and Core Asset in Communicating Value of Medicines (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404507 Tue, 28 Nov 2006 21:33:00 +0100 404507 Como Paso Inicial en la Estrategia de Transformación y Evaluación de Todas las Unidades de Negocio, Pfizer Alineará la Organización de Ventas en EE.UU. para Apoyar sus Productos Clave y las Necesidades de los Clientes http://www.medworm.com/index.php?rid=404508&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D127 Pfizer Dice que los Representantes son una Ventaja Competitiva Crítica y un Bien Clave en la Comunicación de Valores de los Medicamentos (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404508 Tue, 28 Nov 2006 13:38:00 +0100 404508 Organon and Pfizer Discontinue Their Collaboration on Asenapine http://www.medworm.com/index.php?rid=404509&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D125 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404509 Tue, 28 Nov 2006 07:05:00 +0100 404509 Pfizer Invites Public to Listen to Webcast of November 30 Meeting With Analysts http://www.medworm.com/index.php?rid=404510&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D124 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404510 Wed, 22 Nov 2006 19:46:00 +0100 404510 Pfizer Announces Settlement With Teva on Patents Covering Cancer Medicine and Antibiotic http://www.medworm.com/index.php?rid=404511&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D123 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404511 Tue, 21 Nov 2006 13:45:00 +0100 404511 Intensive Lipitor Therapy Reduced Heart Attack and Stroke By One-Third In Patients With Chronic Kidney Disease, New Analysis Shows http://www.medworm.com/index.php?rid=404512&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D122 * Patients with heart disease and chronic kidney disease who took intensive Lipitor therapy (80 mg) reduced their risk of heart attack and stroke by 32 percent compared with patients taking low-dose Lipitor (10 mg). (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404512 Wed, 15 Nov 2006 21:06:00 +0100 404512 Results of New Combined Analysis Concludes Patients at Risk for Glaucoma Will Benefit From Risk Assessment Tool http://www.medworm.com/index.php?rid=404513&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D121 - New data confirm a five-year risk assessment tool will help ophthalmologists better predict which patients have an increased risk of developing glaucoma (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404513 Wed, 15 Nov 2006 17:22:00 +0100 404513 Pfizer Animal Health Agrees to Acquire Embrex, Inc., the Leader in 'In Ovo' Poultry Vaccine-Delivery Technology http://www.medworm.com/index.php?rid=404514&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D120 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404514 Wed, 15 Nov 2006 13:30:00 +0100 404514 Arkansas and Pfizer Announce a New Partnership to Encourage the State’s Children and their Families to Embrace Healthier Eating and Fitness http://www.medworm.com/index.php?rid=404515&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D119 Innovative Public Health Improvement Initiative Provides Community-based Education and Support Services in Three Arkansas School Districts (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404515 Thu, 02 Nov 2006 17:13:56 +0100 404515 Pfizer Updates Preliminary Results of Torcetrapib/Atorvastatin Clinical Trials as Abstract for Phase 3 Study is Released http://www.medworm.com/index.php?rid=404516&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D118 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404516 Tue, 31 Oct 2006 14:20:00 +0100 404516 European Patent Office Supports Validity of Lipitor Patent http://www.medworm.com/index.php?rid=404517&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D117 Madrid, Spain Court of Appeal Confirms Pfizer's Patent Claims (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404517 Fri, 27 Oct 2006 16:40:00 +0100 404517 Dennis A. Ausiello To Join Pfizer Board of Directors http://www.medworm.com/index.php?rid=404519&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D116 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404519 Thu, 26 Oct 2006 12:00:00 +0100 404519 Pfizer Declares a 24-Cent Fourth-Quarter, 2006, Dividend http://www.medworm.com/index.php?rid=404518&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D115 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404518 Thu, 26 Oct 2006 12:00:00 +0100 404518 Pfizer Assists World Health Organization in Search for New Treatments Against Diseases of the Developing World http://www.medworm.com/index.php?rid=404520&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D114 Company Opens its Compound Library to Help Search for New Anti-Parasitic Medicines (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404520 Thu, 26 Oct 2006 09:00:00 +0100 404520 U.S. Appeals Court Denies Ranbaxy Petition for Rehearing Regarding Main Patent in Lipitor Case http://www.medworm.com/index.php?rid=404521&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D113 - - - (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404521 Mon, 23 Oct 2006 18:33:00 +0100 404521 Pfizer to Transform In Rapidly Changing Healthcare Environment http://www.medworm.com/index.php?rid=404522&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D112 - Company Delivers Solid Third-Quarter 2006 Results, Led by Revenue Growth of In-Line and New Products, Confirms Previous Full-Year 2006 Guidance for Revenue and Adjusted Diluted EPS(1) (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404522 Thu, 19 Oct 2006 11:03:00 +0100 404522 Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent http://www.medworm.com/index.php?rid=404523&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D111 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404523 Tue, 17 Oct 2006 08:58:00 +0100 404523 Pfizer Names Senior Executive to Head Expanded Worldwide Licensing and Business Development http://www.medworm.com/index.php?rid=404524&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D110 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404524 Fri, 13 Oct 2006 14:11:00 +0100 404524 Pfizer Expands Commitment to Fight Infectious Diseases With Agreement to Acquire Vaccine Company PowderMed Ltd http://www.medworm.com/index.php?rid=404525&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D108 Acquisition Marks Strategic Entry Into DNA-Based Vaccines (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404525 Mon, 09 Oct 2006 12:00:00 +0100 404525 Pfizer Invites Public to Listen to Webcast of October 19 Conference Call with Analysts http://www.medworm.com/index.php?rid=404526&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D107 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404526 Thu, 05 Oct 2006 13:00:00 +0100 404526 Pfizer's Anti-Smoking Pill Champix® Approved in Europe http://www.medworm.com/index.php?rid=404527&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D106 - More Than 1.2 Million Europeans Die of Smoking-Related Diseases Each Year; WHO Estimates the Annual Financial Burden of Smoking in Europe at $165 Billion (euro 130 Billion) by 2010 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404527 Fri, 29 Sep 2006 10:00:00 +0100 404527 Pfizer Expands Research Commitment to Ophthalmology Through Licensing Agreement With Quark Biotech http://www.medworm.com/index.php?rid=404528&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D105 Novel gene target RTP-801 offers a new approach for a potential treatment of age-related macular degeneration (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404528 Tue, 26 Sep 2006 09:00:00 +0100 404528 Pfizer Invites Public to Listen to Webcast of September 26 Investor Conference Presentation http://www.medworm.com/index.php?rid=404529&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D104 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404529 Fri, 22 Sep 2006 20:43:00 +0100 404529 Pfizer Commits $15 Million Through President Clinton's Global Initiative to Address Critical Treatment Gaps in Malaria http://www.medworm.com/index.php?rid=404530&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D103 Patients in Senegal, Ghana and Kenya to Benefit From New Partnership With Leading International and Local Health Organizations (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404530 Wed, 20 Sep 2006 21:27:00 +0100 404530 Lyrica® de pfizer aprobado en europa para el dolor neural de dificil tratamiento http://www.medworm.com/index.php?rid=404531&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D109 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404531 Tue, 19 Sep 2006 11:38:12 +0100 404531 Pfizer Invites Public to Listen to Webcast of September 20 Investor Conference Speech http://www.medworm.com/index.php?rid=404532&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D102 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404532 Mon, 18 Sep 2006 21:41:00 +0100 404532 Pfizer's Lyrica® Approved in Europe for Difficult-to-Treat Nerve Pain http://www.medworm.com/index.php?rid=404533&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D101 - Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404533 Mon, 18 Sep 2006 18:24:00 +0100 404533 Pfizer and TransTech Pharma Enter Into Agreement for the Development and Commercialization of Rage Modulators http://www.medworm.com/index.php?rid=404534&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D100 Agreement Strengthens Pfizer's Neuroscience Research Commitment With Focus on Potential Treatments for Alzheimer's Disease (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404534 Mon, 18 Sep 2006 12:11:00 +0100 404534 Exubera Effective in Diabetes Patients who Have Respiratory Infections or are Exposed to Passive Cigarette Smoke, New Analyses Show http://www.medworm.com/index.php?rid=404535&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D99 - Twice as Many People With Uncontrolled Type 2 Diabetes Would Accept Insulin if Offered Exubera, Even in Countries Where Pens are Commonly Used, Additional Study Shows (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404535 Thu, 14 Sep 2006 07:07:00 +0100 404535 Court in the Netherlands Upholds Basic Lipitor Patent, Prevents Launch of Ranbaxy Product Before November 2011 http://www.medworm.com/index.php?rid=404536&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D98 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404536 Wed, 13 Sep 2006 08:39:00 +0100 404536 Pfizer Invites Public to Listen to Webcast of September 12 Investor Conference Presentation http://www.medworm.com/index.php?rid=404537&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Findex.php%3Fs%3Dpress_releases%26item%3D97 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=404537 Fri, 08 Sep 2006 19:26:00 +0100 404537 FDA Advisory Committee Recommends Approval of Pfizer’s Selzentry for Use in Patients Starting HIV Therapy for the First Time http://www.medworm.com/index.php?rid=2874183&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20091008006176%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry® (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy. “Pfizer is pleased that the Committee has recognized the effectiveness and safety profile of maraviroc in patients who are starting HIV therapy,&# (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2874183 Thu, 01 Jan 1970 00:00:00 +0100 2874183 Pfizer Receives Approval From Australian Competition And Consumer Commission (ACCC) For Pending Acquisition Of Wyeth http://www.medworm.com/index.php?rid=2844773&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090930005475%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the Australian Competition and Consumer Commission (ACCC) has approved the company’s pending acquisition of Wyeth. The ACCC’s decision includes Pfizer’s commitment to divest certain animal health assets in Australia. “We are pleased to have achieved another significant milestone this week with the ACCC’s approval of the pending acquisition,” said Jeff Kindler, chairman and chief executive of (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2844773 Thu, 01 Jan 1970 00:00:00 +0100 2844773 Pfizer Receives Approval from China’s Ministry of Commerce for Pending Wyeth Acquisition http://www.medworm.com/index.php?rid=2841008&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090929005789%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that China’s Ministry of Commerce has approved the company’s pending acquisition of Wyeth. The Ministry’s decision includes Pfizer’s commitment to divest certain animal health assets in China. “We are pleased to have achieved another significant milestone with the Ministry’s approval of the pending transaction,” said Jeff Kindler, Chairman and Chief Executive, Pfizer. The transaction remain (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2841008 Thu, 01 Jan 1970 00:00:00 +0100 2841008 Pfizer and Eisai Continue Aricept Collaboration http://www.medworm.com/index.php?rid=2830671&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090924006229%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute, Pfizer and Eisai will continue to co-promote Aricept in the U.S., Japan and key markets in Europe, and Pfizer will continue to have an exclusive license to sell Aricept in the other countries where it has rights. Pfize (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2830671 Thu, 01 Jan 1970 00:00:00 +0100 2830671 Frances D. Fergusson And John P. Mascotte Elected To Pfizer’s Board Of Directors http://www.medworm.com/index.php?rid=2830670&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090925005324%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the election of Frances D. Fergusson, Ph.D. and John P. Mascotte to its Board of Directors. Dr. Fergusson and Mr. Mascotte, current members of the Board of Directors of Wyeth, will join the Pfizer Board upon the closing of Pfizer’s pending acquisition of Wyeth in accordance with the terms of the merger agreement. Dr. Fergusson is President Emeritus and professor of art at Vassar College, where she became the ninth president in 1986 and (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2830670 Thu, 01 Jan 1970 00:00:00 +0100 2830670 New Survey of People with Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated http://www.medworm.com/index.php?rid=2826717&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090923006133%26newsLang%3Den DEL MAR, Calif.--(BUSINESS WIRE)--In a new online survey, eighty-five percent of people who experience diabetic nerve pain said that their pain was one of the top three most bothersome complications of their diabetes. Despite the fact that people with diabetic nerve pain recognize the condition’s impact on their lives and eighty-four percent of those surveyed said they have discussed the condition with a healthcare provider, just slightly less than half of respondents (49 percent) were tre (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2826717 Thu, 01 Jan 1970 00:00:00 +0100 2826717 Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation http://www.medworm.com/index.php?rid=2826716&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090924005452%26newsLang%3Den BERLIN--(BUSINESS WIRE)--Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy. Updated data from an expansion cohort of a Phase 1 study with PF-02341066 in NSCLC pa (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2826716 Thu, 01 Jan 1970 00:00:00 +0100 2826716 For Sixth Consecutive Year, Pfizer Earns Highest Score In Human Rights Campaign Foundation LGBT Ranking http://www.medworm.com/index.php?rid=2822566&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090923005774%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has earned a score of 100 — the highest possible — in the 2010 Corporate Equality Index, which evaluates U.S.-based businesses on their treatment of lesbian, gay, bisexual and transgender (LGBT) employees, investors and consumers. The Corporate Equality Index — published annually by the Human Rights Campaign Foundation (HRCF), the largest LGBT advocacy organization in the United States — rates businesses using (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2822566 Thu, 01 Jan 1970 00:00:00 +0100 2822566 Pfizer Commended For Leadership In Addressing Climate Change For Third Consecutive Year http://www.medworm.com/index.php?rid=2817457&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090921006303%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc has been commended by the Carbon Disclosure Project (CDP) for its approach to addressing climate change. CDP named Pfizer to its Climate Disclosure Leadership Index, which highlights the company’s climate change disclosure practices. This is the third consecutive year that Pfizer has been recognized by CDP. “As a health care company, Pfizer is very aware of the potential impact of climate change on global health,” said Steve Brooks, vice pr (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2817457 Thu, 01 Jan 1970 00:00:00 +0100 2817457 Pfizer and Wyeth to Divest Certain Animal Health Assets to Boehringer Ingelheim http://www.medworm.com/index.php?rid=2817456&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090921006526%26newsLang%3Den NEW YORK & MADISON, N.J.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they have entered into an agreement with Boehringer Ingelheim to divest certain animal health assets in connection with the regulatory approval process associated with Pfizer’s pending acquisition of Wyeth. Under the terms of the agreement, Boehringer Ingelheim will acquire products, research and manufacturing facilities, located in Fort Dodge, Iowa, as well as related assets and in (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2817456 Thu, 01 Jan 1970 00:00:00 +0100 2817456 Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer’s AROMASIN® (Exemestane Tablets) http://www.medworm.com/index.php?rid=2817455&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090922005718%26newsLang%3Den BERLIN--(BUSINESS WIRE)--Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events (HR=0.82; 95% CI: 0.73-0.92; P=0.0009), compared to women who continued on tamoxifen for a full five years of treatment.1 In addition, IES showed that AROMASIN prolonged over (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2817455 Thu, 01 Jan 1970 00:00:00 +0100 2817455 Pfizer Again Named To Working Mother 100 Best Companies List http://www.medworm.com/index.php?rid=2817454&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090922005906%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc has been named among the 2009 Working Mother 100 Best Companies for its steadfast commitment to family-friendly benefits. Pfizer and the other winning companies are pioneering programs that support families, with 100 percent offering flextime, on-site lactation and telecommuting; and 98 percent offering job-sharing and wellness programs—numbers that dwarf those seen nationwide. In addition, financial programs available to the 100 Best employees are on (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2817454 Thu, 01 Jan 1970 00:00:00 +0100 2817454 Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents http://www.medworm.com/index.php?rid=2809058&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090918005746%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer,1 updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET),2 and early-stage research of investigational agents PF-023410663 and figitumumab (CP-751,871)4 in patients with non-small cell lung cancer (NSCLC). These data, and over a do (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2809058 Thu, 01 Jan 1970 00:00:00 +0100 2809058 Pfizer Invites Public to View and Listen to Webcast of October 20 Conference Call with Analysts http://www.medworm.com/index.php?rid=2776715&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090909005138%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 20, 2009. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2009 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2776715 Thu, 01 Jan 1970 00:00:00 +0100 2776715 Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference http://www.medworm.com/index.php?rid=2773732&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090908006061%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a discussion with David Simmons, President and General Manager, Established Products, and Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2009 at 8:35 a.m. Eastern Daylight Saving Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global He (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2773732 Thu, 01 Jan 1970 00:00:00 +0100 2773732 Heading Back to School: Veterinarians Combine Stethoscopes with Microscopes http://www.medworm.com/index.php?rid=2755436&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090901006134%26newsLang%3Den DENVER--(BUSINESS WIRE)--Private practice isn’t for everyone, but for graduating veterinary students facing an average of $120,000 in debt, it often is the only logical choice. A new program—the Pfizer Animal Health–Morris Animal Foundation (MAF) Veterinary Fellowship for Advanced Study—gives current practitioners necessary financial support while they pursue a veterinary research career. The program commits a minimum of nearly $1.7 million over four years toward a soluti (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2755436 Thu, 01 Jan 1970 00:00:00 +0100 2755436 Pfizer Concludes Previously Disclosed Settlement Agreement With U.S. Department Of Justice Regarding Past Promotional Practices http://www.medworm.com/index.php?rid=2755434&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090902005690%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005. The final agreement also resolves other DOJ investigations involving alleged past off-label promotional practices concerning Zyvox, Geodon and Lyrica, allegations related to certain pay (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2755434 Thu, 01 Jan 1970 00:00:00 +0100 2755434 Novel Biomarkers, Including CRP, Did Not Predict Risk Of Cardiovascular Events In Patients With Heart Disease Who Were Treated With A Statin http://www.medworm.com/index.php?rid=2750334&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090831005855%26newsLang%3Den BARCELONA, Spain--(BUSINESS WIRE)--For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain. By contrast, traditional lipid risk factors were strong predictors of cardiovascular events. The findings are based on a new post h (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2750334 Thu, 01 Jan 1970 00:00:00 +0100 2750334 Pfizer Inc Sponsors 7th Biennial U.S.–Africa Business Summit http://www.medworm.com/index.php?rid=2736302&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090826005527%26newsLang%3Den WASHINGTON--(BUSINESS WIRE)--The Corporate Council on Africa (CCA) announced today that Pfizer Inc will sponsor the 7th Biennial U.S. – Africa Business Summit: Realizing the Investment Power of Africa, to be held at the Walter E. Washington Convention Center in Washington, D.C., September 29 – October 1, 2009. At a Pfizer-sponsored workshop titled Mobilizing Resources for Strengthening African Health Systems: A Case Study of Pfizer’s Global Health Fellows, Charles Shafran, form (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2736302 Thu, 01 Jan 1970 00:00:00 +0100 2736302 Pfizer And Private Access Announce Plans To Develop Online Community To Accelerate Clinical Research http://www.medworm.com/index.php?rid=2714468&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090819005806%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Recognizing that patient participation in clinical trials is the key to progress in medical research, Pfizer Inc announced today that it has entered into a collaboration with Private Access, (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2714468 Thu, 01 Jan 1970 00:00:00 +0100 2714468 President Clinton, Pfizer, and Mylan Announce New Agreements to Lower Prices of Medicines for Patients with Drug-Resistant HIV in Developing Countries http://www.medworm.com/index.php?rid=2677136&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090806005853%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--President Bill Clinton announced two important and complementary agreements today to enable better, more affordable treatments for patients on second-line antiretroviral (ARV) therapy for (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2677136 Thu, 01 Jan 1970 00:00:00 +0100 2677136 Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease http://www.medworm.com/index.php?rid=2655759&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090730005524%26newsLang%3Den NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of a Phase 3 trial of the investigational drug dimebon (latrepirdine)* in patients (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2655759 Thu, 01 Jan 1970 00:00:00 +0100 2655759 Pfizer, Kano State Reach Settlement Of Trovan Cases http://www.medworm.com/index.php?rid=2655758&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090730005769%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced it has reached agreement with the Kano State government in Nigeria to settle Kano State’s claims arising from the 1996 Trovan clinical study, which was (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2655758 Thu, 01 Jan 1970 00:00:00 +0100 2655758 Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference http://www.medworm.com/index.php?rid=2652222&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090729005753%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, at the BMO Capital Markets 9th Annual Focus On (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2652222 Thu, 01 Jan 1970 00:00:00 +0100 2652222 Pfizer Announces Partnership With Shanghai Institutes For Biological Sciences For Drug Discovery Activities http://www.medworm.com/index.php?rid=2652221&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090729005723%26newsLang%3Den SHANGHAI, China--(BUSINESS WIRE)--Pfizer today announced a joint initiative with the Shanghai Institutes for Biological Sciences (SIBS) to support fundamental research in China. As part of the initiative, Pfizer China (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2652221 Thu, 01 Jan 1970 00:00:00 +0100 2652221 Pfizer and Fudan University Announce Joint Graduate Program in Clinical Research http://www.medworm.com/index.php?rid=2652219&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090729005783%26newsLang%3Den SHANGHAI, China--(BUSINESS WIRE)--Pfizer today announced a partnership with Fudan University to establish a graduate program in Clinical Data Management and Statistical Programming. This three year Masters Degree (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2652219 Thu, 01 Jan 1970 00:00:00 +0100 2652219 Pfizer Reports Second-Quarter 2009 Results; Increases Full-Year 2009 Adjusted Diluted EPS(1) Guidance http://www.medworm.com/index.php?rid=2624144&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090722005480%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2624144 Thu, 01 Jan 1970 00:00:00 +0100 2624144 96-Week MERIT ES Analysis Shows Efficacy Of Pfizer’s HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naïve HIV Patients; Results Consistent With 48-Week Analysis http://www.medworm.com/index.php?rid=2618807&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090721005286%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--At 96-week follow up, data from the MERIT ES analysis show that treatment-naïve HIV patients taking Celsentri/Selzentry (maraviroc), in combination with Combivir® (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2618807 Thu, 01 Jan 1970 00:00:00 +0100 2618807 Pfizer Receives Approval From European Commission For Pending Acquisition Of Wyeth http://www.medworm.com/index.php?rid=2612691&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090717005661%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company’s pending acquisition of Wyeth. The (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2612691 Thu, 01 Jan 1970 00:00:00 +0100 2612691 Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer’s Disease At ICAD Annual Meeting http://www.medworm.com/index.php?rid=2604467&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090715005684%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2604467 Thu, 01 Jan 1970 00:00:00 +0100 2604467 Pfizer To Appeal Canadian Federal Court Decision On Company’s Norvasc® Patent http://www.medworm.com/index.php?rid=2586575&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20090709005916%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it is disappointed by the Canadian Federal Court’s decision declaring invalid its patent covering amlodipine besylate, the active ingredient in Norvasc®, (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2586575 Thu, 01 Jan 1970 00:00:00 +0100 2586575 Pfizer Invites Public to View and Listen to Webcast of January 22 Meeting with Analysts http://www.medworm.com/index.php?rid=2567136&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070222005640%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts being held on (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567136 Thu, 01 Jan 1970 00:00:00 +0100 2567136 Pfizer's Sutent(R) is Granted Full Marketing Authorization for First-Line Use in Advanced Kidney Cancer in the European Union http://www.medworm.com/index.php?rid=2567135&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070222005624%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that Sutent® (sunitinib malate) has received the European Commission’s (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567135 Thu, 01 Jan 1970 00:00:00 +0100 2567135 Pfizer Animal Health Completes Acquisition of Embrex, Inc. http://www.medworm.com/index.php?rid=2567134&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070222005615%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health, a division of Pfizer Inc (NYSE: PFE) today announced the completion of its acquisition of Embrex, Inc. (NASDAQ: (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567134 Thu, 01 Jan 1970 00:00:00 +0100 2567134 Pfizer Announces Priorities to Drive Improved Performance, Position Company for Future Success and Enhance Total Shareholder Return http://www.medworm.com/index.php?rid=2567133&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070222005606%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Chairman and Chief Executive Officer Jeffrey B. Kindler today announced the company's immediate priorities to drive improved (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567133 Thu, 01 Jan 1970 00:00:00 +0100 2567133 Pfizer Achieves Key 2006 Financial Targets http://www.medworm.com/index.php?rid=2567132&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070222005780%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc: (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567132 Thu, 01 Jan 1970 00:00:00 +0100 2567132 Pfizer Gains Favorable Ruling From Canadian Court on Lipitor Basic Patent, Will Appeal Ruling on Calcium Salt Patent http://www.medworm.com/index.php?rid=2567131&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070222005566%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it will appeal a decision by the Canadian Federal Court in Toronto denying its application to block approval of (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567131 Thu, 01 Jan 1970 00:00:00 +0100 2567131 Court Rules In Pfizer's Favor In Norvasc Patent Case, Finds Synthon Obtained Patent By Inequitable Conduct http://www.medworm.com/index.php?rid=2567130&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070222005554%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--The federal district court in the Eastern District of Virginia (Alexandria) has ruled that Synthon IP obtained, by inequitable conduct, two (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567130 Thu, 01 Jan 1970 00:00:00 +0100 2567130 Pfizer to Acquire BioRexis to Access Novel Technology Platform and Early Stage Diabetes Pipeline http://www.medworm.com/index.php?rid=2567129&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070222005539%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement to acquire BioRexis Pharmaceutical Corporation, a privately-held (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567129 Thu, 01 Jan 1970 00:00:00 +0100 2567129 New Analysis Shows That Intensive Lipitor Therapy Cuts the Risk of Hospitalizations Due to Heart Failure in Patients with Coronary Heart Disease http://www.medworm.com/index.php?rid=2567128&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070314005895%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Patients with coronary heart disease who took Lipitor® (atorvastatin calcium) 80 mg tablets reduced their risk of (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567128 Thu, 01 Jan 1970 00:00:00 +0100 2567128 Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label http://www.medworm.com/index.php?rid=2567127&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070222005509%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) has approved new labeling of Sutent® (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567127 Thu, 01 Jan 1970 00:00:00 +0100 2567127 Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe http://www.medworm.com/index.php?rid=2567126&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070222005493%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567126 Thu, 01 Jan 1970 00:00:00 +0100 2567126 Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product http://www.medworm.com/index.php?rid=2567125&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070314005457%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S -- the largest pharmaceutical wholesaler in (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567125 Thu, 01 Jan 1970 00:00:00 +0100 2567125 Pfizer Board of Directors Elects Constance J. Horner to Serve as Lead Director http://www.medworm.com/index.php?rid=2567124&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070314005464%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer said today that Constance J. Horner, a member of the company's Board of Directors since 1993, has been elected lead director effective (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567124 Thu, 01 Jan 1970 00:00:00 +0100 2567124 Pfizer Wins Challenge to Norvasc Patent by Mylan http://www.medworm.com/index.php?rid=2567123&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070314005471%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a federal court in the Western District of Pennsylvania (Pittsburgh) has upheld the company's U.S. patent covering the (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567123 Thu, 01 Jan 1970 00:00:00 +0100 2567123 Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients http://www.medworm.com/index.php?rid=2567122&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070314005489%26newsLang%3Den LOS ANGELES--(BUSINESS WIRE)--At this week's major HIV/AIDS research meeting, Pfizer presented pivotal data of its experimental medicine, maraviroc, which tackles HIV in an (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567122 Thu, 01 Jan 1970 00:00:00 +0100 2567122 Lipitor Significantly Reduced the Risk of Serious Cardiovascular Events Compared With Simvastatin in an 80,000-Patient Analysis of a Real-World Managed Care Database http://www.medworm.com/index.php?rid=2567121&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070314005496%26newsLang%3Den BUENA VISTA, Fla.--(BUSINESS WIRE)--A retrospective analysis of a large U.S. managed care database showed that patients who took Pfizer's cholesterol-lowering medicine (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567121 Thu, 01 Jan 1970 00:00:00 +0100 2567121 Lipitor Receives FDA Approval for Five New Indications in Patients With Heart Disease http://www.medworm.com/index.php?rid=2567120&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070314005507%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Lipitor® (atorvastatin calcium) (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567120 Thu, 01 Jan 1970 00:00:00 +0100 2567120 Pfizer Invites Public to View and Listen to Webcasts of Pfizer Presentations at Healthcare Conferences http://www.medworm.com/index.php?rid=2567119&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070314005520%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) invites investors and the general public to view and listen to webcasts of presentations by Vice Chairman David Shedlarz at (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567119 Thu, 01 Jan 1970 00:00:00 +0100 2567119 Pfizer Honored as a Top American Corporation for Women Business Enterprises http://www.medworm.com/index.php?rid=2567118&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070320006250%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer today announced that the Women’s Business Enterprise National Council (WBENC), the nation (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567118 Thu, 01 Jan 1970 00:00:00 +0100 2567118 Pfizer Wins Celebrex Patent Challenge by Generic Manufacturer Teva http://www.medworm.com/index.php?rid=2567117&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070320006295%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that a federal court in the District of New Jersey (Newark) has upheld the three main U.S. patents covering Celebrex, the company (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567117 Thu, 01 Jan 1970 00:00:00 +0100 2567117 Exubera: A Highly Effective Needle-Free Alternative to Diabetes Pills and Insulin Injections http://www.medworm.com/index.php?rid=2567116&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070425005908%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--In response to recent news coverage of Exubera, Pfizer believes people with diabetes and their families should have the following information (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567116 Thu, 01 Jan 1970 00:00:00 +0100 2567116 Pfizer Statement in Response to Appeals Court Decision in Norvasc Patent Case http://www.medworm.com/index.php?rid=2567115&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070322005917%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeals for the Federal Circuit has issued a decision reversing a lower court ruling upholding the (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567115 Thu, 01 Jan 1970 00:00:00 +0100 2567115 Pfizer to Present New Lipitor Data, Including Results from Three Large Atherosclerosis Imaging Trials, at the American College of Cardiology Meeting http://www.medworm.com/index.php?rid=2567114&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070323005408%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer announced today that new data regarding the effect of Lipitor (atorvastatin calcium) on atherosclerosis, cardiovascular events such as heart attacks and (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567114 Thu, 01 Jan 1970 00:00:00 +0100 2567114 Pfizer Announces Launch of Generic Amlodipine Besylate Product by Greenstone http://www.medworm.com/index.php?rid=2567113&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070323005696%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567113 Thu, 01 Jan 1970 00:00:00 +0100 2567113 Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis http://www.medworm.com/index.php?rid=2567112&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070326005917%26newsLang%3Den NEW ORLEANS--(BUSINESS WIRE)--Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567112 Thu, 01 Jan 1970 00:00:00 +0100 2567112 Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients http://www.medworm.com/index.php?rid=2567111&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070326006206%26newsLang%3Den NEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567111 Thu, 01 Jan 1970 00:00:00 +0100 2567111 Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show http://www.medworm.com/index.php?rid=2567110&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070327006171%26newsLang%3Den NEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) lowered hospitalization costs by (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567110 Thu, 01 Jan 1970 00:00:00 +0100 2567110 Pharmacia Subsidiaries Reach $34.7 Million Settlement with DOJ; Resolve Allegations of Improper Activities Prior to Acquisition by Pfizer http://www.medworm.com/index.php?rid=2567109&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070402006143%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer announced today that two subsidiaries of Pharmacia have reached separate settlements with the United States Department of Justice to address charges (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567109 Thu, 01 Jan 1970 00:00:00 +0100 2567109 Pfizer Invites Public to Listen to Webcast of April 20 Conference Call with Analysts http://www.medworm.com/index.php?rid=2567108&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070409005507%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Friday, April 20. The (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567108 Thu, 01 Jan 1970 00:00:00 +0100 2567108 Pfizer Invites Public to Access Webcast of April 26 Annual Meeting of Shareholders http://www.medworm.com/index.php?rid=2567107&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070419006073%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567107 Thu, 01 Jan 1970 00:00:00 +0100 2567107 Pfizer Delivers Solid First-Quarter 2007 Results, Updates Full-Year Expectations for 2007 and 2008 http://www.medworm.com/index.php?rid=2567106&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070420005230%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer: (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567106 Thu, 01 Jan 1970 00:00:00 +0100 2567106 FDA Advisory Committee Recommends Accelerated Approval of Pfizer's Maraviroc for Treatment-Experienced Patients Infected with CCR5-tropic HIV-1 http://www.medworm.com/index.php?rid=2567105&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070424006547%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted unanimously (12-0) (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567105 Thu, 01 Jan 1970 00:00:00 +0100 2567105 Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds http://www.medworm.com/index.php?rid=2567104&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070426005515%26newsLang%3Den PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) today announced a worldwide collaboration to develop and commercialize (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567104 Thu, 01 Jan 1970 00:00:00 +0100 2567104 Pfizer Focused on Delivering the Value Customers Expect and Shareholders Deserve, CEO Kindler Tells Shareholders http://www.medworm.com/index.php?rid=2567103&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070426005803%26newsLang%3Den SOUTH BEND, Ind.--(BUSINESS WIRE)--In remarks at the annual shareholders meeting, Pfizer Chairman and Chief Executive Officer Jeffrey B. Kindler said, “We (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567103 Thu, 01 Jan 1970 00:00:00 +0100 2567103 Pfizer Declares a 29-cent Second-Quarter, 2007, Dividend http://www.medworm.com/index.php?rid=2567102&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070426005819%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 29-cent second-quarter, 2007, dividend on the company's common stock, payable June 5, 2007, to shareholders (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567102 Thu, 01 Jan 1970 00:00:00 +0100 2567102 Pfizer Invites Public to View and/or Listen to Webcasts of Pfizer Participation at Healthcare Conferences http://www.medworm.com/index.php?rid=2567101&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070427005544%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Vice Chairman David Shedlarz at the 32nd (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567101 Thu, 01 Jan 1970 00:00:00 +0100 2567101 Pfizer Foundation's ConnectHIV Initiative Provides $7.5 Million in Grants to Community-Based AIDS Service Organizations Across 10 States http://www.medworm.com/index.php?rid=2567100&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070430005154%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation today announced the names of 20 U.S. community-based AIDS service organizations (ASOs) chosen to participate in ConnectHIV, the (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567100 Thu, 01 Jan 1970 00:00:00 +0100 2567100 Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014 http://www.medworm.com/index.php?rid=2567099&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070430006349%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc reported today that the Federal Court of Appeal of Canada has reversed a lower court ruling that would have permitted generic manufacturer Novopharm to (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567099 Thu, 01 Jan 1970 00:00:00 +0100 2567099 Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show http://www.medworm.com/index.php?rid=2567098&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070501006565%26newsLang%3Den BOSTON--(BUSINESS WIRE)--Significantly more patients treated with Pfizer’s Lyrica reduced their pain by 50 percent or more compared with placebo, according to (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567098 Thu, 01 Jan 1970 00:00:00 +0100 2567098 Pfizer Launches Online Initiative Disclosing Its U.S. Post-Marketing Commitments http://www.medworm.com/index.php?rid=2567097&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070502005726%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has launched an online site to provide up-to-date, user-friendly information on the status of its U.S. post-marketing commitments. (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567097 Thu, 01 Jan 1970 00:00:00 +0100 2567097 Counterfeit Drugs Put Lives at Risk http://www.medworm.com/index.php?rid=2567096&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D95574%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070514005570%26newsLang%3Den BRUSSELS, Belgium--(BUSINESS WIRE)--Pfizer welcomes the 1st European Parliamentary symposium on pharmaceuticals “Putting an end to (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567096 Thu, 01 Jan 1970 00:00:00 +0100 2567096 Pharmacia and Upjohn Will Appeal Verdict in Simon Case, 'Ruling is Not Supported by the Evidence' http://www.medworm.com/index.php?rid=2567095&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070515006646%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer said its subsidiary, Pharmacia and Upjohn, will appeal today’s jury verdict linking its product, Provera, with plaintiff Merle (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567095 Thu, 01 Jan 1970 00:00:00 +0100 2567095 Pfizer Says Research and Development Head John LaMattina Will Retire This Year http://www.medworm.com/index.php?rid=2567094&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070520005047%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer said today that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567094 Thu, 01 Jan 1970 00:00:00 +0100 2567094 Pfizer Supports Complete Smoking Ban in Public Areas and Improved Access to Smoking Cessation Treatments across Europe http://www.medworm.com/index.php?rid=2567093&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D96773%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070524005315%26newsLang%3Den BRUSSELS, Belgium--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) (LSE:PFZ) welcomes the European Commission’s Green Paper on smoke free environments (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567093 Thu, 01 Jan 1970 00:00:00 +0100 2567093 Pfizer Animal Health Medicine Used to Treat Whales http://www.medworm.com/index.php?rid=2567092&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070526005012%26newsLang%3Den RIO VISTA, Calif.--(BUSINESS WIRE)--Responding to a request from the Marine Mammal Center, Pfizer Animal Health (PAH) has donated an antibiotic which was used today to treat the two humpback (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567092 Thu, 01 Jan 1970 00:00:00 +0100 2567092 Pfizer Will Immediately Seek to Appeal Lipitor Patent Ruling in Norway http://www.medworm.com/index.php?rid=2567091&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070529005741%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc. said today that it will immediately seek to appeal a ruling by the Borgarting Court of Appeal in Oslo, Norway that four of Pfizer (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567091 Thu, 01 Jan 1970 00:00:00 +0100 2567091 New Pfizer Oncology Data Across Numerous Cancer Types to be Presented at ASCO http://www.medworm.com/index.php?rid=2567090&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070529005833%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer said today that results showing potential across numerous types of cancer, such as melanoma, thyroid, liver, non-small cell lung (NSCLC), colorectal (CRC) (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567090 Thu, 01 Jan 1970 00:00:00 +0100 2567090 Pfizer's Growing Strength in Oncology http://www.medworm.com/index.php?rid=2567089&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070529005834%26newsLang%3Den --(BUSINESS WIRE)--At next week’s American Society of Clinical Oncology Meeting, Pfizer will present new information that underscores the depth and breadth of (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567089 Thu, 01 Jan 1970 00:00:00 +0100 2567089 Pfizer Invites Public to View and Listen to Webcast of June 4 Pfizer Analyst Meeting at ASCO http://www.medworm.com/index.php?rid=2567088&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070529005837%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts to be held on Monday, June 4, at 6:00 (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567088 Thu, 01 Jan 1970 00:00:00 +0100 2567088 UK Body Recommends Pfizer's Champix (varenicline) for Smokers http://www.medworm.com/index.php?rid=2567087&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D97197%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070530005488%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has recommended Champix (varenicline) for (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567087 Thu, 01 Jan 1970 00:00:00 +0100 2567087 Pfizer and Express Scripts Sign Agreement http://www.medworm.com/index.php?rid=2567086&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070530005673%26newsLang%3Den ST. LOUIS & NEW YORK--(BUSINESS WIRE)--Express Scripts, Inc. (NASDAQ: ESRX), and Pfizer Inc (NYSE: PFE), today announced an agreement providing for Pfizer’s (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567086 Thu, 01 Jan 1970 00:00:00 +0100 2567086 New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer http://www.medworm.com/index.php?rid=2567085&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070602005029%26newsLang%3Den CHICAGO--(BUSINESS WIRE)--Pfizer said today that clinical trials examining its different cancer-fighting approaches showed activity in patients with non-small cell lung cancer (NSCLC). Data (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567085 Thu, 01 Jan 1970 00:00:00 +0100 2567085 Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer Says http://www.medworm.com/index.php?rid=2567084&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070605006049%26newsLang%3Den CHICAGO--(BUSINESS WIRE)--Data on Pfizer’s investigational compound CP-675,206, which works by a novel mechanism of action and represents a new (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567084 Thu, 01 Jan 1970 00:00:00 +0100 2567084 Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show http://www.medworm.com/index.php?rid=2567083&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070603005057%26newsLang%3Den CHICAGO--(BUSINESS WIRE)--Pfizer announced today that single-agent, oral SUTENT® (sunitinib malate) prolonged progression-free survival (PFS) (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567083 Thu, 01 Jan 1970 00:00:00 +0100 2567083 New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy http://www.medworm.com/index.php?rid=2567082&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070604005791%26newsLang%3Den CHICAGO--(BUSINESS WIRE)--Pfizer announced today that axitinib (AG-013736), an investigational oral, selective inhibitor of VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2, (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567082 Thu, 01 Jan 1970 00:00:00 +0100 2567082 Pfizer to Advance Three Key Oncology Compounds into Phase 3 Trials in 2007, Company Tells Financial Analysts http://www.medworm.com/index.php?rid=2567081&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070605005297%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced that it is advancing key compounds through clinical development at a meeting with financial analysts yesterday in connection with the American (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567081 Thu, 01 Jan 1970 00:00:00 +0100 2567081 Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at June 14 Healthcare Conference http://www.medworm.com/index.php?rid=2567080&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070607005873%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Olivier Brandicourt, Senior Vice President of Pfizer (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567080 Thu, 01 Jan 1970 00:00:00 +0100 2567080 Slentrol, First Medication to Combat Canine Obesity, Now Available by Prescription http://www.medworm.com/index.php?rid=2567079&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070612005727%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health (NYSE: PFE) today announced that SLENTROL™ (dirlotapide), the first (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567079 Thu, 01 Jan 1970 00:00:00 +0100 2567079 Pfizer Discontinues Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer http://www.medworm.com/index.php?rid=2567078&cid=s_34477_34_f&fid=34477&url=http%3A%2F%2Fmms.businesswire.com%2Fbwapps%2Fmediaserver%2FViewMedia%3Fmgid%3D90590%26vid%3D2http%3A%2F%2Fmediaroom.pfizer.com%2Fportal%2Fsite%2Fpfizer%2Findex.jsp%3FndmViewId%3Dnews_view%26ndmConfigId%3D1017152%26newsId%3D20070620006009%26newsLang%3Den NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today the discontinuation of a development program in lung cancer for PF-3512676, an investigational compound, in combination with (Source: Pfizer Media Center - News Releases) Pfizer Media Center - News Releases news http://www.medworm.com/rss/comments.php?id=2567078 Thu, 01 Jan 1970 00:00:00 +0100 2567078